Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) was the recipient of a significant increase in short interest in the month of December. As of December 29th, there was short interest totalling 9,749,519 shares, an increase of 9.6% from the December 15th total of 8,894,839 shares. Based on an average trading volume of 2,362,490 shares, the short-interest ratio is presently 4.1 days. Currently, 14.2% of the shares of the company are sold short.
Ampio Pharmaceuticals (NYSEAMERICAN AMPE) opened at $2.93 on Friday. The stock has a market capitalization of $190.19, a P/E ratio of -14.65 and a beta of 0.51. Ampio Pharmaceuticals has a 1 year low of $0.38 and a 1 year high of $4.95.
Separately, ValuEngine upgraded Ampio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 11th.
Ampio Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company’s two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema.
Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.